Clinical trial
2 Arm Study of Clofarabine IV in MDS Patients
NCT00422032 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00422032 |
|---|---|
| Title | 2 Arm Study of Clofarabine IV in MDS Patients |
| Official title | Phase II Randomized Study of Two Different Schedules of Intravenous Clofarabine in Myelodysplastic Syndrome (MDS) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Leukemia |
| Intervention type | Drug |
| Interventions | Clofarabine |
| Enrollment | 60 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2011 |
| Completion | Nov 1, 2011 |
| First posted | Jan 15, 2007 |
| Last update posted | Jul 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: